DrStore Healthcare Services, a connected healthcare and medical device ecosystem company, has introduced an integrated real-time monitoring platform through its smart medical device and technology platform, Tracky. The new system enables clinicians and pharmaceutical companies to track patient outcomes for GLP-1 therapies in India by consolidating multiple health data streams into a unified digital ecosystem.
By combining clinical data with lifestyle insights, the platform aims to improve patient management, enhance therapy monitoring, and generate meaningful real-world evidence for GLP-1 treatments used in diabetes and weight management.
Rising Demand for GLP-1 Therapies Creates Need for Continuous Monitoring
In recent years, GLP-1 therapies have gained significant traction globally and in India for treating diabetes and supporting weight loss. As adoption grows, however, healthcare experts are identifying a major challenge—the lack of continuous, structured data to track patient outcomes in real-world settings.
Currently, most therapy monitoring occurs during periodic clinical visits, which leaves clinicians with limited visibility into how patients respond to treatment between appointments. Consequently, healthcare providers often struggle to optimise therapy, monitor adherence, and identify side effects early.
To address this gap, Tracky has developed a platform designed to provide continuous, real-time visibility into patient health and therapy outcomes.
Integrating Multiple Health Data Streams into One Platform
As per the press release, Tracky’s platform integrates diverse health data sources to create a comprehensive and continuous view of metabolic health. By bringing multiple parameters together, the system enables longitudinal monitoring of patient progress.
Key data streams integrated into the platform include:
- Continuous Glucose Monitoring (CGM) data
- Body composition tracking
- Food logs and calorie tracking
- Physical activity levels
- Wearable device inputs
Through this integrated approach, clinicians can monitor patient progress in real time, identify early signs of complications, and make informed decisions regarding dosage adjustments and therapy management.
Supporting Better Clinical Decisions in GLP-1 Therapy
Within the context of GLP-1 therapy for diabetes and weight management, the Tracky platform enables healthcare providers to track several critical indicators simultaneously.
For instance, clinicians can monitor glucose levels, weight changes, activity patterns, and dietary behaviour to understand how patients respond to treatment. As a result, they can:
- Adjust medication dosage more precisely
- Detect and manage side effects earlier
- Improve patient adherence to therapy
- Identify lifestyle factors affecting outcomes
By correlating clinical parameters with behavioural and lifestyle data, the platform helps clinicians develop more personalised and data-driven treatment strategies.
Generating Real-World Evidence for Pharmaceutical Companies
In addition to supporting clinicians, the platform offers significant value for pharmaceutical companies running GLP-1 therapy programmes.
Traditionally, pharmaceutical firms face challenges in collecting real-world evidence on therapy performance outside controlled clinical trials. However, Tracky’s platform provides a structured framework for:
- Large-scale patient monitoring programmes
- Adherence tracking
- Outcome analysis across diverse patient populations
Consequently, pharmaceutical partners can gain deeper insights into treatment effectiveness in real-world conditions.
Addressing the Challenge of Post-Therapy Sustainability
Another emerging concern with GLP-1 therapies relates to maintaining health outcomes after discontinuation of treatment. While clinical trials have shown strong results in weight loss and metabolic improvement, sustaining these benefits over time remains difficult.
Tracky addresses this challenge by combining continuous health monitoring with lifestyle insights. This approach enables clinicians to guide patients in maintaining healthy behaviours and metabolic improvements even after therapy cycles end.
Expert Perspectives on Continuous Monitoring
Speaking about the platform, Neeraj Katare, Founder of Tracky, highlighted the importance of linking therapy with real-world data.
“GLP therapies are transforming metabolic care, but their full impact depends on how effectively we monitor and understand patient outcomes beyond the prescription,” he said. “Our goal is to build a continuous data layer that connects therapy with real-world patient insights. This enables better clinical decisions and generates meaningful evidence for pharmaceutical partners.”
Similarly, Dr. Jothydev Kesavadev, Chairman of Jothydev’s Diabetes and Research Center in Trivandrum, emphasized the importance of real-world monitoring.
“While GLP-1 therapies are producing strong clinical outcomes, tracking patient progress outside clinical settings remains a challenge. A platform that integrates multiple health parameters and enables continuous monitoring can help bridge this gap and support proactive patient management,” he noted.
Dr. Banshi Saboo, Chairman of the International Diabetes Federation – South East Asia, also highlighted the clinical value of real-time monitoring.
“One of the biggest challenges with GLP therapies is the limited visibility into patient response between clinic visits. Real-time monitoring of parameters such as glucose, weight, and activity can significantly improve treatment titration, side-effect management, and clinical decision-making,” he said.
Adoption by Pharmaceutical Companies
Several leading pharmaceutical companies have already integrated Tracky’s platform into their GLP therapy programmes. Through this collaboration, they can monitor patient adherence and therapy outcomes at scale, while also generating valuable real-world evidence to support treatment strategies.
By combining connected medical devices, real-time analytics, and integrated health data, Tracky aims to reshape how GLP-1 therapies are monitored and managed in India’s evolving metabolic healthcare landscape.